FDA ANDA · ANDA075091
CARBIDOPA AND LEVODOPA
Sponsor: MYLAN
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA075091
TYPE
ANDA
ORIGINAL APPROVAL
1999-09-30
LATEST ACTION
2026-10-08
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET, EXTENDED RELEASE · ORAL
CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 50MG, LEVODOPA 200MG · TABLET, EXTENDED RELEASE · ORAL
Approval history
2026-10-08Labeling · Supplement 36 · standardAP
2015-05-27Labeling · Supplement 26 · standardAP
2012-05-14Labeling · Supplement 24AP
2002-10-01Manufacturing (CMC) · Supplement 8AP
2002-06-12Manufacturing (CMC) · Supplement 7AP
2001-11-07Labeling · Supplement 6AP
2000-08-11Manufacturing (CMC) · Supplement 4AP
2000-08-11Manufacturing (CMC) · Supplement 5AP
2000-04-21Manufacturing (CMC) · Supplement 1AP
2000-04-21Labeling · Supplement 2AP
2000-02-04Labeling · Supplement 3AP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →